Screening and verification of hub genes involved in osteoarthritis using bioinformatics

JUNXIONG XIE¹²*, ZHIQIN DENG¹*, MURAD ALAHDAL¹*, JIANQUAN LIU¹, ZHE ZHAO¹, XIAOQIANG CHEN¹, GUANGHUI WANG¹, XIAOTIAN HU¹, LI DUAN¹, DAPING WANG¹² and WENCUI LI¹

¹Guangdong Provincial Research Center for Artificial Intelligence and Digital Orthopedic Technology, Hand and Foot Surgery Department, Shenzhen Second People's Hospital (The First Hospital Affiliated to Shenzhen University), Shenzhen, Guangdong 518000;
²University of South China, School of Clinical Medicine, Hengyang, Hunan 421001, P.R. China

Received May 29, 2020; Accepted October 16, 2020

DOI: 10.3892/etm.2021.9761

Abstract. Osteoarthritis (OA) is one of the most common causes of disability and its development is associated with numerous factors. A major challenge in the treatment of OA is the lack of early diagnosis. In the present study, a bioinformatics method was employed to filter key genes that may be responsible for the pathogenesis of OA. From the Gene Expression Omnibus database, the datasets GSE55457, GSE12021 and GSE55235 were downloaded, which comprised 59 samples. Of these, 30 samples were from patients diagnosed with osteoarthritis and 29 were normal. Differentially expressed genes (DEGs) were obtained by downloading and analyzing the original data using bioinformatics. The Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathways were analyzed using the Database for Annotation, Visualization and Integrated Discovery online database. Protein-protein interaction network analysis was performed using the Search Tool for the Retrieval of Interacting Genes/proteins online database. BSCL2 lipid droplet biogenesis associated, seipin, FOS-like 2, activator protein-1 transcription factor subunit (FOSL2), cyclin-dependent kinase inhibitor 1A (CDKN1A) and kinectin 1 (KTN1) genes were identified as key genes by using Cytoscape software. Functional enrichment revealed that the DEGs were mainly accumulated in the ErbB, MAPK and PI3K-Akt pathways. Reverse transcription-quantitative PCR analysis confirmed a significant reduction in the expression levels of FOSL2, CDKN1A and KTN1 in OA samples. These genes have the potential to become novel diagnostic and therapeutic targets for OA.

Introduction

Osteoarthritis (OA) is a chronic degenerative disease of the joints, characterized by cartilage degeneration, chronic inflammation and decreased normal joint function (1). Its clinical manifestations are mainly local pain and limited activity of the joint (2). OA commonly occurs in females over 55 and males over 65 years of age (3). With economic improvements and the aging of the population, an increasing number of patients are diagnosed with OA, which is now the most common cause of disability worldwide. The number of patients with OA is estimated to be >47 million in the US and is forecast to increase to ~67 million in 2030 (25% of the adult population) (4). The quality of life of patients with OA is significantly lower than that of others and poses great physical, psychological and financial burdens.

Although the pathogenesis of OA has received much clinical attention, genetic factors associated with the development of this disease remain elusive (5). Previously, OA was thought to be a heritable disease, but later studies have not determined any clear hereditary factors in the pathogenesis of OA (6). However, bioinformatics has advanced the study of OA and has identified specific genes involved in disease severity (7). Similar advances have been made in the study of rheumatoid arthritis (8,9). While hub genes involved in OA have been identified as key genes in its pathogenesis, no comprehensive genetic analysis has yet been performed (10). Several studies have performed gene expression profiling of OA samples and screened thousands of differentially expressed genes (DEGs) using high-throughput sequencing technology and other advanced techniques (11,12). However, a comprehensive analysis of all gene data collected is still missing. An integrated bioinformatics approach is able to predict and identify the hub genes involved in OA.

In the present study, three datasets, GSE12021 (13), GSE55457 (14) and GSE55235 (11), were analyzed. Screening

*Contributed equally

Key words: osteoarthritis, hub genes, bioinformatics, GEO database
of DEGs between OA patients and normal controls was performed. Gene Ontology (GO) and DEG pathway enrichment, protein-protein interaction (PPI) network and functional module analyses were then performed to explore the underlying molecular mechanisms of the pathogenesis of OA.

Materials and methods

**Microarray data.** National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) is a public online repository for high-throughput gene queries and high-throughput gene expression detection for the global research community (15). It was used in the present study to obtain OA-related genes and their expression values were downloaded for further analysis. The GSE12021, GSE55235 and GSE55457 gene expression profiles were downloaded from the GEO database. Subsequently, three datasets from OA patients and normal controls (GSE55235, GSE55457 and GSE77298) were used for analysis; however, the data were downloaded without OA stage identification.

**Screening of DEGs by GEO2R.** The GEO2R online database (https://www.ncbi.nlm.nih.gov/gds/) was used to identify DEGs between OA samples and normal controls from three databases (GSE55235, GSE55457 and GSE77298); log fold change (FC)>1 and P<0.01 were considered to be DEGs. Venn diagrams were used to screen for common significant differences among DEGs.

**GO enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.** For GO analysis, functional terms enriched by the DEGs were determined in three distinct categories representing different biological aspects: Molecular function (MF), biological process (BP) and cellular component (CC) (16). KEGG pathways were determined to analyze gene functions and link the genetic information in the genome with the biological functional information of genes. The Database for Annotation, Visualization and Integrated Discovery (DAVID; https://david.ncifcrf.gov/) was used to perform GO analysis and KEGG analysis.

**Construction of PPI network.** PPI network construction was performed using the Search Tool for the Retrieval of Interacting Genes/proteins (STRING) database (https://string-db.org/cgi/network.pl). Subsequently, the DEGs were imported into Cytoscape software (http://www.cytoscape.org/) for better visualization. Next, the MCODE plugin was used to screen for key DEGs among all DEGs.

**Reverse transcription-quantitative (RT-q)PCR verification.** RT-qPCR was used to verify the four key genes. The RNA samples obtained from chondrocytes were extracted and transcribed into complementary DNA by an RNAiso Plus and PrimeScript® RT reagent kit (Takara Bio, Inc.). The DyNAmyo SYBR-Green and qPCR systems (Takara Bio, Inc.) were used to analyze gene expression. Fill the ice box with samples. A ribozyme free 200 µl EP tube was placed on ice, after which 1,000 ng RNA samples were added. A total of 1 µl gDNA Eraser and 1 µl 5X gDNA Eraser Buffer was subsequently added to samples. Finally, RNase Free ddH₂O was added to samples making a total volume of 10 µl. Amplification 2 min at 42°C. Then at 4°C, 4 µl 5X PrimeScript Buffer 2, 4 µl RNase Free ddH₂O, 1 µl PrimeScript Enzyme Mix I and 1 µl RT Prime Mix was added to samples. Amplification 15 min at 37°C and 5 sec at 85°C. A total of 20 µl cDNA was obtained by reverse transcription. Subsequently, 5 µl SYBR Premix Ex Taq II with 3.5 µl dd H₂O, 0.2 µl ROX, 0.5 µl cDNA, 0.4 µl PCR Forward Primer (10 µM) and 0.4 µl PCR Reverse Primer (10 µM) was added 96-well plates. The plates were run on the fluorescence quantitative PCR instrument, using the following cycling conditions: 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec, 60°C for 30 sec, 90°C for 15 sec and 60°C for 60 sec. The paired primers for the four key genes are listed in Table I. All samples were compared with GAPDH. The 2^ΔΔCq method was used to quantify the relative gene expression levels (17).

**Cell culture and immunofluorescence assays.** The collection and culturing of chondrocytes was performed as described in detail in previous studies by our group (18-20). Specimens of the knee joint and femoral head were collected from patients undergoing joint replacement surgery at the Bone and Joint Department of Shenzhen Second People's Hospital (Shenzhen, China) between December 2017 and October 2019. According to the patient's imageological diagnosis, all OA samples obtained were from patients with OA of grades III and IV in Kellgren-Lawrence classification (21). In addition, as the control, the samples of patients with femoral neck fracture on radiographic diagnosis were used. The average age of the patients was 78.44±3.42 years in the control group, including 9 patients (2 males and 7 females), and 66.60±4.53 years in the OA group, including 5 patients (5 females). The following procedures were performed under sterile conditions. The samples were washed with normal saline three times and a surgical blade was used to cut the cartilage tissue blocks to final sizes of approximately 1x1x1 mm. The samples were incubated with collagenase type II (1 mg/ml; cat. no. C6885; Sigma-Aldrich; Merck KGaA) working liquid and oscillated for digestion for 8-12 h at 37°C. The cell suspension was then divided into two parts. One part was added to complete chondrocyte culture medium (containing 10% FBS; Gibco; Thermo Fisher Scientific, Inc.), 1% penicillin and streptomycin, 1% HEPES, 1% ascorbic acid, 1% proline solution and 1% non-essential amino acids) and cultured in a CO₂ incubator. The other part was centrifuged and resuspended and cells were dropped onto a glass slide for subsequent experiments. The present study was approved by the Ethics Committee of Shenzhen Second People's Hospital (Shenzhen, China) and written informed consent was obtained from all subjects.

For the immunofluorescence experiment, methods similar to those of other studies were used (22,23). The steps of immunofluorescence labeling of target protein were as follows: After washing the cells with PBS two times, the cells were fixed with paraformaldehyde for 15 min. The cells were then washed with PBS six times for 5 min each. Triton X100 (0.5%, diluted with PBS) was added, and samples were incubated for 15 min at room temperature. Cells were again washed by PBS six times for 5 min each. The cells were then blocked with 5% bovine serum albumin (Amresco LLC) for 2 h at room temperature and then washed with 0.5% BSA six times for 5 min each. The samples were then incubated with primary
antibody (rabbit anti-Collagen II/FITC conjugated antibody; cat. no. bs-10589R-FITC; BIOSS) at 4˚C overnight. As these conjugated fluorescent dye primary antibodies demonstrated a strong specificity, secondary antibodies were not required. Subsequently, the cells were washed with 0.5% BSA six times for 5 min each. Subsequently, the cells were washed by PBS six times for 5 min each. DAPI (Thermo Fisher Scientific, Inc.) was added for 5 min and cells were washed with PBS three times for 5 min each. Images of fluorescently labeled cells were acquired with an LSM800 confocal microscope (Zeiss AG).

Statistical analysis. Prism 8 (GraphPad Software, Inc.) was used to generate figures. Experimental data were statistically analyzed using SPSS 19.0 software (IBM Corp.). Student’s t-test was used to assess differences between groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Screening of DEGs. Genes with significant differences in expression (P<0.051 and |log FC|>1) between the OA samples and normal controls were screened in the GEO2R website and 181 DEGs, including 48 upregulated and 133 downregulated genes, were identified (Fig. 1).

GO functional enrichment analysis. The functions of the 181 DEGs were classified using DAVID. In the GO category MF, these DEGs were significantly enriched in protein-DNA binding, RNA binding and protein homodimerization activity. In addition, in the category CC, the DEGs were significantly enriched in the nucleoplasm, nucleus, cytoplasm and plasma membrane. However, in the category BP, there were fewer genes enriched compared with the other categories (Fig. 2 and Table II). The upregulated DEGs were mainly enriched in the extracellular space and plasma membrane. The downregulated DEGs were significantly enriched in the nucleoplasm, nucleus and cytoplasm, and were involved in protein binding.

KEGG signaling pathway analysis. DEGs were mainly enriched in the MAPK and PI3K-Akt signaling pathways (Fig. 3) according to the KEGG analysis. The signaling pathways of downregulated DEGs were mainly enriched in osteoclast differentiation, MAPK signaling, TNF signaling, Epstein-Barr virus infection and insulin signaling. Upregulated genes were mainly enriched in influenza A signaling (Table III).

PPI network builds and MCODE analysis. To further analyze the relationships among all DEGs, PPI networks were constructed, including 161 nodes and 375 edges. The network included 181 protein interactions with combined scores of >0.4 (Fig. 4A). By further analyzing the PPI networks, four modules were detected using the MCODE plugin in Cytoscape. According to the MCODE score, key genes in four modules were screened, including BSCL2 lipid droplet biogenesis associated, seipin (BSCL2), FOS-like 2, activator protein-1 transcription factor subunit (FOSL2), cyclin-dependent kinase inhibitor 1A (CDKN1A) and kinectin 1 (KTN1) (Fig. 4B-D).

Validation of key genes. To verify the results, the expression levels of four key genes were determined in human articular chondrocytes (Fig. 5). First, normal chondrocytes (Ctrl group) and osteoarthritis chondrocytes (OA group) were obtained from patients undergoing joint replacement and subsequently, cells were cultured and stained with toluidine blue (Fig. 5A and B). To further identify the two types of cells, immunofluorescence was used to observe differences in the expression of type II collagen, which was decreased significantly in OA chondrocytes (Fig. 5C). Subsequently, the expression levels of the four key genes were determined by RT-qPCR. The results indicated that the expression level of BSCL2 in OA samples was increased but with no significant difference (P>0.05, n=3;
Fig. 5F), while the expression levels of FOSL2, CDKN1A and KTN1 were significantly decreased. The differences between OA and normal chondrocytes in the expression levels of the four key genes were consistent with the analytical results of PCR (P<0.05, n=3; Fig. 5D, E and G).

**Discussion**

OA is considered to be the most common cause of disability (24); it seriously affects the quality of life, creating physical, psychological and economic burdens for patients. The diagnosis and treatment of OA require an interdisciplinary approach. Bioinformatics is a tool widely used to predict potential target genes for numerous diseases. In the present study, three sets of data from patients with OA and normal controls were analyzed by using GEO2R. Between the OA and control groups, 181 DEGs were identified, including 48 upregulated and 133 downregulated genes. The upregulated DEGs were mainly enriched in the extracellular space and plasma membrane. Downregulated DEGs were significantly enriched in functional terms associated with the nucleoplasm, nucleus, cytoplasm and protein binding, and this explains that the main difference between patients with OA and individuals without OA is in the cartilage cells. Cellular changes are an important part of the process of OA. OA is a chronic degenerative disease characterized by cartilage defects and chondrocytes are the only cell type in articular cartilage (25). Cartilage cell apoptosis is a key part of OA (26). The present study suggested that the downregulated gene CDKN1A, which regulates the occurrence and development of apoptosis, may participate

---

Table II. Significant enrichment of DEGs in osteoarthritis.

| Category | Term | Description | Gene count | P-value |
|----------|------|-------------|------------|---------|
| **A, Downregulated DEGs** | | | | |
| BP | GO:0071850 | Mitotic cell cycle arrest | 2 | 8.41x10^-2 |
| BP | GO:0045821 | Positive regulation of glycolytic process | 2 | 9.02x10^-2 |
| BP | GO:0010839 | Negative regulation of keratinocyte proliferation | 2 | 9.02x10^-2 |
| BP | GO:0070498 | Interleukin-1-mediated signaling pathway | 2 | 9.02x10^-2 |
| BP | GO:0097009 | Energy homeostasis | 2 | 9.64x10^-2 |
| CC | GO:0005654 | Nucleoplasm | 39 | 2.45x10^-6 |
| CC | GO:0005634 | Nucleus | 56 | 5.71x10^-5 |
| CC | GO:0005737 | Cytoplasm | 48 | 4.78x10^-4 |
| CC | GO:0005667 | Transcription factor complex | 5 | 3.59x10^-2 |
| CC | GO:0000790 | Nuclear chromatin | 5 | 3.59x10^-2 |
| MF | GO:0005515 | Protein binding | 80 | 3.11x10^-4 |
| MF | GO:0042803 | Protein homodimerization activity | 15 | 4.81x10^-4 |
| MF | GO:0044822 | poly(A) RNA binding | 19 | 6.78x10^-4 |
| MF | GO:0000166 | Nucleotide binding | 9 | 2.78x10^-3 |
| MF | GO:0003677 | DNA binding | 22 | 4.73x10^-3 |

| **B, Upregulated DEGs** | | | | |
| BP | GO:0007155 | Cell adhesion | 6 | 4.97x10^-3 |
| BP | GO:0016525 | Negative regulation of angiogenesis | 3 | 1.00x10^-2 |
| BP | GO:0030336 | Negative regulation of cell migration | 3 | 2.25x10^-3 |
| BP | GO:0071257 | Cellular response to electrical stimulus | 2 | 2.89x10^-2 |
| BP | GO:0007399 | Nervous system development | 4 | 3.27x10^-2 |
| CC | GO:0005615 | Extracellular space | 11 | 6.34x10^-4 |
| CC | GO:0005578 | Proteinaceous extracellular matrix | 5 | 3.02x10^-3 |
| CC | GO:0005886 | Plasma membrane | 18 | 5.37x10^-3 |
| CC | GO:0005788 | Endoplasmic reticulum lumen | 4 | 9.15x10^-3 |
| CC | GO:0030133 | Transport vesicle | 3 | 1.93x10^-2 |
| MF | GO:0001786 | Phosphatidylserine binding | 3 | 2.97x10^-3 |
| MF | GO:0008201 | Heparin binding | 4 | 5.12x10^-3 |

BP, biological process; CC, cellular component; MF, molecular function; GO, Gene Ontology; DEG, differentially expressed gene.
Further analysis indicated that these DEGs were mainly enriched in the ErbB, MAPK and PI3K-Akt signaling pathways. These pathways are associated with chondrocyte apoptosis in OA. MAPK modulates joint inflammation and joint damage (27). The major pathological changes in OA are cartilage damage and poor healing (1), so the MAPK pathway is able to promote the aggravation of OA or rheumatoid arthritis to exert an important role in the pathogenesis of arthritis (26,28). Erb activates PI3K to generate phosphatidylinositol-3,4,5-triphosphate that effectively activates the Akt pathway. Apoptosis-associated proteins are competitively inhibited by the Akt pathway. Thus, recruiting this gene may promote cell survival and inhibit cell apoptosis (29). There is a definite correlation between the degree of cartilage damage and chondrocyte apoptosis (26). Therefore, inhibiting chondrocyte apoptosis may be effective in regulating cartilage degeneration during OA. Animal experiments have indicated that the use of MAPK inhibitors effectively

| Term                  | Description                          | Gene count | P-value     |
|-----------------------|--------------------------------------|------------|-------------|
| hsa04380              | Osteoclast differentiation            | 7          | 9.17x10^-4  |
| hsa04010              | MAPK signaling pathway                | 9          | 1.46x10^-3  |
| hsa04668              | TNF signaling pathway                 | 6          | 2.30x10^-3  |
| hsa05169              | Epstein-Barr virus infection          | 6          | 4.05x10^-3  |
| hsa04910              | Insulin signaling pathway             | 6          | 6.81x10^-3  |

| Term                  | Description                          | Gene count | P-value     |
|-----------------------|--------------------------------------|------------|-------------|
| hsa05164              | Influenza A                          | 3          | 8.21x10^-3  |

DEG, differentially expressed gene; hsa, *Homo sapiens*. 

Figure 2. GO analysis results of hub genes. GO analysis classified the differentially expressed genes into three groups: Molecular function, biological process and cellular component. GO, Gene Ontology.

Figure 3. Kyoto Encyclopedia of Genes and Genomes analysis results of differentially expressed genes. The color gradient represents the P-value; the size of the dots represents the gene number.
improves inflammation and joint degeneration in mice with OA (30), which demonstrates the potential of inhibiting MAPK in OA treatment. The PI3K/Akt pathway is associated with TNF-α-induced activation of OA fibroblast-like synoviocytes, which may be involved in OA pathogenesis (31). It promotes cartilage degeneration, subchondral bone function damage and inflammation during OA (32). The use of MAPK inhibitors reduces the pathological changes of OA (31). CDKN1A is able to activate the AKT pathway and induce MAPK8 to participate in the inactivation of MAPK, further reducing apoptosis (33,34). It has been reported that CDKN1A is significantly downregulated in the synovium of arthritis patients and
is associated with inhibition of chondrocyte proliferation (35), suggesting that upregulation of CDKN1A may have a positive role in the early treatment of OA.

By contrast, the expression of BSCL2 in OA samples was significantly increased compared with that in normal samples. BSCL2 has a key role in lipogenesis, lipid metabolism and lipid droplet synthesis (36). The loss of BSCL2 may lead to serious disorders in metabolic dysfunction and a significant reduction in fat (37), whereas upregulation of BSCL2 may lead to weight gain. Obesity is a major cause of OA (38), and thus, upregulation of BSCL2 may induce its development. Furthermore, various transforming (FOS) proteins affect the physiology of chondrocytes, osteoblasts and osteoclasts (39). FOSL2 is the key regulator of leptin expression in fat cells (40) and its deficiency is able to promote obesity. In the present study, its low expression in OA samples was noted, which is consistent with obesity being a leading cause of OA (38). Recent studies have indicated that FOSL2 is suppressed in the early hypertrophy state of chondrocytes, suggesting that this gene is strongly associated with the early initiation of OA (41). Therefore, overexpressed BSCL2 and decreased expression of FOSL2 in OA samples promotes obesity in patients with OA, and their regulation may have a positive role in the prevention of OA. Furthermore, KTN1 is a receptor on the endoplasmic reticulum (42) that has an important part in adjusting protein biosynthesis in cells (43). A proteomics analysis of human mesenchymal stem cells undergoing inhibited chondrogenesis indicated reduced levels of KTN1 (44), suggesting an association of KTN1 with chondrogenesis enhancement. Thus, enhancing KTN1 may induce chondrocyte proliferation.

Of note, the present study had a limitation: When NCBI GEO was used to obtain the microarray data, the information on the OA stage was unclear or the diagnosis of the OA classification by different doctors was biased. Therefore, it is difficult to ensure that all patients whose data were downloaded had the same OA classification. In order to confirm certain key genes that regulate the occurrence of osteoarthritis identified in bioinformatics screenings, more data and further experimental verification are still required.

A limitation of the present study was that cells were prepared using collagenase II. Further experiments are therefore required to determine whether this may have affected results.

In conclusion, bioinformatics and experimental data suggested that BSCL2, FOSL2, CDKN1A and KTN1 are key DEGs in OA compared with normal samples. Therapeutic targeting of these genes may positively contribute to the treatment and prevention of OA and consequent disability. One limitation of the present study is the limited amount of collected data. Further analyses and experiments are required prior to performing some potential targets.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 81800785, 81972085 and 81772394), the Natural Science Foundation of Guangdong Province (grant no. 2018A0303100027), the Sanming Project of Shenzhen Health and Family Planning Commission (grant no. SZSM201612086), Shenzhen Science and Technology Planning (grant no. JCYJ20180228163401333), the Doctor Innovation Project of Shenzhen Health System (grant no. SZBC2018015) and the Shenzhen Peacock Project (grant no. KQTD20170331100838136).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors’ contributions
WL and DW conceived and designed the current study. JX, ZD and MA drafted the manuscript. JX, ZD and MA created the schematic. JL, MA, ZZ, XC, GW, XH and LD interpreted the data and revised the manuscript critically for important intellectual content. JX performed the bioinformatics analysis and laboratory experiments. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate
The study was reviewed and approved by the First Affiliated Hospital of Shenzhen University Health Science Center Research Ethics Committee (Shenzhen, China). All patients provided written informed consent for publication.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Kraus VB, Blanco FJ, Englund M, Karsdal MA and Lohmander LS: Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage 23: 1233-1241, 2015.
2. Winter AR, Collins JE and Katz JN: The likelihood of total knee arthroplasty following arthroscopic surgery for osteoarthritis: A systematic review. BMC Musculoskeletal Disorders 18: 408, 2017.
3. Jimenez G, Cobo-Molinos J, Antich C and Lopez-Ruiz E: Osteoarthritis: Trauma vs. disease. Adv Exp Med Biol 1059: 63-83, 2018.
4. Hootman JM and Helmick CG: Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 54: 226-229, 2006.
5. MacGregor AJ, Li Q, Spector TD and Williams FM: The genetic contribution to radiographic hip osteoarthritis in women: Results of a classic twin study. Arthritis Rheum 54: 226-229, 2006.
6. MacGregor AJ, Li Q, Spector TD and Williams FM: The genetic influence on radiographic osteoarthritis is site specific at the hand, hip and knee. Rheumatology (Oxford) 48: 277-280, 2009.
7. Moazed-Godara FC, Hofner M, Gruber G, Weinhaeusel A, Stradner MH, Angerer H, Peichsler D, Lobherger B, Giehr M, Leitner A, et al.: Epigenetic differences in human cartilage between mild and severe OA. J Orthop Res 32: 1636-1645, 2014.
8. Lu W and Li G: Identification of key genes and pathways in rheumatoid arthritis gene expression profile by bioinformatics. Acta Reumatol Port 43: 109-131, 2018.
9. Duan H, Zhai KF, Khan GJ, Chen Y, Cao YY, Cai LY, Yang HJ, Wang YC, Liu Q, Wang D, Liu W, Li Z and Wang D: E2 regulates MMP-13 via targeting miR-140 in IL-1β-induced extracellular matrix degradation in human chondrocytes. Arthritis Res Ther 18: 105, 2016.
10. Li H, Bai D, Wang J, Xu Z, Yan S and Liu G: Identification of key mRNAs and microRNAs in the pathogenesis and progression of osteoarthritis using microarray analysis. Mol Med Rep 16: 5569-5566, 2017.
11. Woertz D, Huber R, Kupfer P, Pohlers D, Pfaff M, Driesch D, Häupl T, Koczan D, Stiehl P, Guthke R and Kinne RW: Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation. Arthritis Res Ther 18: R84, 2016.
12. Broeren MG, de Vries M, Bennink MB, van Lent PL, van der Kraan PM, Koenders MI, Thurlings RM and van de Loo FA: Functional tissue analysis reveals successful cryopreservation of human osteoarthritic synovium. PLoS One 11: e0167076, 2016.
13. Huber R, Hummer C, Güttler M, Kozenz D, Guthke R and Kinne RW: Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane. Arthritis Res Ther 10: R98, 2008.
14. Ye Y, Bao C and Fan W: Overexpression of miR-101 May target DUSP1 to promote the cartilage degradation in rheumatoid arthritis. J Comput Biol 26: 1067-1079, 2019.
15. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al.: NCBI GEO: Archive for functional genomics data sets-update. Nucleic Acids Res 41: D999-1004, 2013.
16. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al.: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet 25: 25-29, 2000.
17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25: 402-408, 2001.
18. Jia Z, Zhu F, Li X, Liang Q, Zhuo Z, Huang J, Duan L, Xiong J and Wang D: Repair of osteochondral defects using injectable chitosan-based hydrogel encapsulated synovial fluid-derived mesenchymal stem cells in a rabbit model. Mater Sci Eng C Mater Biol Appl 99: 541-551, 2019.
19. Liang Y, Duan L, Xiong J, Zhu W, Liu Q, Wang D, Liu W, Li Z and Wang D: E2 regulates MMP-13 via targeting miR-140 in IL-1β-induced extracellular matrix degradation in human chondrocytes. Arthritis Res Ther 18: 105, 2016.
20. Duan L, Liang Y, Ma B, Zhu W and Wang D: Epigenetic regulation in chondrocyte phenotype maintenance for cell-based cartilage repair. Am J Transl Res 7: 2127-2140, 2015.
21. Kohn MD, Sassoon AA and Fernando ND: Classifications in Brief: Keigil-Lawrence classification of osteoarthritis. Clin Orthop Related Res 474: 1886-1893, 2016.
22. Zhai KF, Duan H, Khan GJ, Xu H, Han FK, Cao WG, Gao GZ, Shan LL and Wei ZJ: Salicin from Alangium Chineseme ameliorates rheumatoid arthritis by modulating the NrF2-HO-1-ROS pathways. J Agric Food Chem 66: 6073-6082, 2018.
23. Zhai KF, Duan H, Chen Y, Khan GJ, Cao WG, Gao GZ, Shan LL and Wei ZJ: Apatosis effects of imperatorin on synoviocytes in rheumatoid arthritis through mitochondrial/caspase-mediated pathways. Food Funct 9: 2070-2079, 2018.
24. Wight L, Owen D, Goldbloom D and Knupp M: Pure ankle dislocation: A systematic review of the literature and estimation of incidence. Injury 48: 2027-2034, 2017.
25. Fassbender HG: Role of chondrocytes in the development of osteoarthritis. Am J Med 83: 17-24, 1987.
26. Hwang HS and Kim HA: Chondrocyte apoptosis in the pathogenesis of osteoarthritis. Int J Mol Sci 16: 26035-26042, 2015.
27. Sundarrajyan M, Boyle DL, Chabaud-Riou M, Hammadaker M and Firestein GS: Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 48: 2450-2460, 2003.
28. Zhai KF, Duan H, Cui CY, Cao YY, Si JL, Yang HJ, Wang YC, Cao WG, Gao GZ and Wei ZJ: Liquiritin from Glycyrrhiza uralseni attenuating rheumatoid arthritis via reducing inflammation, suppressing angiogenesis, and inhibiting MAPK signaling pathway. J Agric Food Chem 67: 2070-2079, 2019.
29. Wight L, Owen D, Goldbloom D and Knupp M: Pure ankle dislocation: A systematic review of the literature and estimation of incidence. Injury 48: 2027-2034, 2017.
30. Fassbender HG: Role of chondrocytes in the development of osteoarthritis. Am J Med 83: 17-24, 1987.
31. Hwang HS and Kim HA: Chondrocyte apoptosis in the pathogenesis of osteoarthritis. Int J Mol Sci 16: 26035-26042, 2015.
32. Sundarrajyan M, Boyle DL, Chabaud-Riou M, Hammadaker M and Firestein GS: Expression of the MAPK kinases MKK-4 and MKK-7 in rheumatoid arthritis and their role as key regulators of JNK. Arthritis Rheum 48: 2450-2460, 2003.
33. Zhai KF, Duan H, Cui CY, Cao YY, Si JL, Yang HJ, Wang YC, Cao WG, Gao GZ and Wei ZJ: Liquiritin from Glycyrrhiza uralsenis attenuating rheumatoid arthritis via reducing inflammation, suppressing angiogenesis, and inhibiting MAPK signaling pathway. J Agric Food Chem 67: 2070-2079, 2019.
34. Park HK, Kim IH, Kim J and Nam TJ: Induction of apoptosis and the regulation of ErbB signaling by laminin 111-2 in human colon cancer cells. Int J Mol Sci 32: 291-293, 2015.
35. Maudens P, Seemayer CA, Pfeiferle F, Jordan O and Alleman L: Nanocrystals of a potent p38 MAPK inhibitor embedded in microparticles. Therapeutic effects in inflammatory and mechanic murine models of osteoarthritis. J Control Release 276: 102-112, 2018.
36. Liu S, Cao C, Zhang Y, Liu G, Ren W, Ye Y and Sun T: PI3K/Akt inhibitor partly decreases TNF-α-induced activation of fibroblast-like synoviocytes in osteoarthritis. J Orthop Surg Res 14: 425, 2019.
37. Sun Q, Luo J, Guo J, Yao X, Jing X and Guo F: The PI3K/AKT/mTOR signalling pathway in osteoarthritis: A narrative review. Osteoarthritis Cartilage 28: 400-409, 2020.
38. Kleinsimon S, Longmuss E, Rolf J, Jäger S, Eggert A, Delebinski C and Seifert G: GADD45A and CDKNA1 are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway. Sci Rep 8: 5750, 2018.
34. Yarushkin AA, Mazin ME, Yunusova AY, Korchagina KV, Pustylnyak YA, Prokopjeva EA and Pustylnyak VO: CAR-mediated repression of Cdkn1a(p21) is accompanied by the Akt activation. Biochem Biophys Res Commun 504: 361‑366, 2018.

35. Gang X, Xu H, Si L, Zhu X, Yu T, Jiang Z and Wang Y: Treatment effect of CDKN1A on rheumatoid arthritis by mediating proliferation and invasion of fibroblast-like synoviocytes cells. Clin Exp Immunol 194: 220‑230, 2018.

36. Mori E, Fujikura J, Noguchi M, Nakao K, Matsabara M, Sone M, Taura D, Kasakabe T, Ebihara K, Tanaka T, et al: Impaired adipogenic capacity in induced pluripotent stem cells from lipodystrophic patients with BSCL2 mutations. Metabolism 65: 543‑556, 2016.

37. McIlroy GD, Mitchell SE, Han W, Delibegovic M and Rochford JJ: Female adipose tissue‑specific Bscl2 knockout mice develop only moderate metabolic dysfunction when housed at thermoneutrality and fed a high‑fat diet. Sci Rep 8: 17863, 2018.

38. Francisco V, Perez T, Pino J, López V, Franco E, Alonso A, Gonzalez‑Gay MA, Mera A, Lago F, Gómez R and Gualillo O: Biomechanics, obesity, and osteoarthritis. The role of adipokines: When the levee breaks. J Orthop Res 36: 594‑604, 2018.

39. Bozec A, Bakiri L, Jimenez M, Schinke T, Amling M and Wagner EF: Fra-2/AP‑1 controls bone formation by regulating osteoblast differentiation and collagen production. J Cell Biol 190: 1093‑1106, 2010.

40. Wrann CD, Eguchi J, Bozec A, Xu Z, Mikkelsen T, Gimble J, Nave H, Wagner EF, Ong SE and Rosen ED: FOSL2 promotes leptin gene expression in human and mouse adipocytes. J Clin Invest 122: 1010‑1021, 2012.

41. He X, Ohba S, Hojo H and McMahon AP: AP‑1 family members act with Sox9 to promote chondrocyte hypertrophy. Development 143: 3012‑3023, 2016.

42. Abe E, Okawa S, Sugawara M, Watanabe S and Toyoshima I: Identification of ER membrane targeting signal of kinectin. Neurosci Lett 413: 238‑240, 2007.

43. Ong LL, Lin PC, Zhang X, Chia SM and Yu H: Kinectin‑dependent assembly of translation elongation factor‑1 complex on endoplasmic reticulum regulates protein synthesis. J Biol Chem 281: 33621‑33634, 2006.

44. Martinez Sánchez AH, Omidi M, Wurlitzer M, Wurlitzer M, Fuh MM, Feyerabend F, Schlüter H, Willumeit‑Römer R and Luthringer BJ: Proteome analysis of human mesenchymal stem cells undergoing chondrogenesis when exposed to the products of various magnesium‑based materials degradation. Bioact Mater 4: 168‑188, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.